Congressman Dan Goldman Pushes Supreme Court Justices to Protect Access to Medication Abortion

Goldman Signs Amicus Brief Urging Supreme Court to Reverse Extremist Fifth Circuit Ruling Restricting Access to Medication Abortion Mifepristone

Read the Amicus Brief Here

Washington, DC – Congressman Goldman (NY-10) joined 262 members of Congress in submitting an amicus brief urging the Supreme Court to protect access to the medication abortion drug Mifepristone and reverse the Fifth Circuit Court of Appeal’s politically motivated decision to restrict access and revoke the Food and Drug Administration’s 2016 and 2021 regulatory actions increasing access to Mifepristone.

This amicus brief follows an April 2023 brief filed with the Supreme Court urging the Court to issue a stay on the Fifth Circuit’s ruling and allow Mifepristone to remain accessible until the Supreme Court could hear the case.

"Medication abortion is safe, it is effective, and it is health care,” Congressman Dan Goldman said. “The experts at the FDA have approved it for more than 20 years, but now partisan judges have overruled the FDA’s experts. The Supreme Court must reverse this dangerous ruling and reaffirm that the responsibility for prescription drug safety should rest with the health care experts, not the courts. Religious or political views simply cannot stand in the middle of a woman, her doctor, and her freedom to get an abortion. Medication abortion must continue to be available for women nationwide.”

Congressman Goldman is continuously fighting to protect abortion rights and access across the United States.

In March of 2023, Congressman Goldman cosponsored the 'Women’s Health Protection Act' to fully codify the protections of Roe v. Wade into law and the ‘Ensuring Women’s Right to Reproductive Freedom Act,’ which would prohibit any person acting under state law from punishing or restricting Americans traveling for reproductive health care.

In June, Congressman Goldman and Congresswoman Judy Chu (CA-28) led their colleagues in urging retail pharmacies to obtain the certification required to dispense Mifepristone.

Click here to read the amicus brief.

###